中国癌症杂志 ›› 2021, Vol. 31 ›› Issue (9): 789-798.doi: 10.19401/j.cnki.1007-3639.2021.09.004

• 论著 • 上一篇    下一篇

神经胶质瘤中NCAPD2的表达水平及生物学意义

徐 然 1,2 ,王馨悦 1,2 ,冯麟媛 1,2 ,韩安娜 1,2 ,王艺璇 1,2 ,杨万山 1,2 ,刘 超 3   

  1. 1. 延边大学肿瘤研究中心,吉林 延吉 133002 ;
    2. 民族地区高发肿瘤病理生物学国家民委重点实验室(延边大学),吉林 延吉 133002 ;
    3. 延边大学附属医院神经内科,吉林 延吉 133002
  • 出版日期:2021-09-30 发布日期:2021-10-08
  • 通信作者: 刘 超 E-mail: 1075428098@qq.cm
  • 基金资助:
    国家自然科学基金地区基金项目(31760313);吉林省科技厅中央引导地方科技发展资金项目(202002021JC);吉林省教育厅十三五科学技术研究项目(JJKH20180912KJ)。

Expression and biological significance of NCAPD2 in glioma

XU Ran 1,2 , WANG Xinyue 1,2 , FENG Linyuan 1,2 , HAN Anna 1,2 , WANG Yixuan 1,2 , YANG Wanshan 1,2 , LIU Chao   

  1. 1. Cancer Research Center, School of Medicine, Yanbian University, Yanji 133002, Jilin Province, China; 2. Key Laboratory of Pathobiology of High Frequency Oncology in Ethnic Minority Areas (Yanbian University), State Ethnic Affairs Commission, Yanji 133002, Jilin Province, China; 3. Department of Neurology, Affiliated Hospital of Yanbian University, Yanji 133002, Jilin Province, China
  • Published:2021-09-30 Online:2021-10-08
  • Contact: LIU Chao E-mail: 1075428098@qq.com

摘要: 背景与目的:NCAPD2是一种蛋白质编码基因,在有丝分裂等细胞增殖过程中发挥关键作用。探究NCAPD2在神经胶质瘤组织中的表达水平及生物学意义。方法:应用GEPIA数据库分析NCAPD2 mRNA在多种恶性肿瘤组织中的表达;运用Ualcan、UCSC Xena和TIMER2.0数据库分析NCAPD2 mRNA在神经胶质瘤中的表达水平。采用免疫组织化学S-P法检测并分析NCAPD2蛋白在正常脑组织和神经胶质瘤组织中的表达情况,以及NCAPD2蛋白的高表达与神经胶质瘤临床病理学特征的关系。采用蛋白质印迹法(Western blot)检测NCAPD2蛋白在神经胶质瘤细胞中的表达水平。进一步使用LinkedOmics数据库探寻与NCAPD2共表达的基因,并采用Metascape数据库和GOplot数据库进行富集分析。结果:数据库分析显示,NCAPD2在多种恶性肿瘤组织中的表达高于正常组织(P < 0.05),且在异柠檬酸脱氢酶1(isocitrate dehydrogenase 1,IDH1)突变型神经胶质瘤中的表达水平高于IDH1野生型(P < 0.05)。免疫组织化学结果显示,NCAPD2蛋白主要表达于细胞核和细胞质中,其在神经胶质瘤组织中的阳性表达率与强阳性表达率显著高于正常脑组织(P < 0.01)。同时NCAPD2蛋白高表达与神经胶质瘤患者的临床分期呈正相关(P < 0.05)。Western blot显示,NCAPD2蛋白在神经胶质瘤细胞中的表达显著高于神经胶质细胞(P < 0.05)。GO富集分析显示,NCAPD2基因主要与细胞周期进程相关(P < 0.01)。结论:NCAPD2在神经胶质瘤中高表达,且与临床分期及细胞周期进程密切相关,预示着NCAPD2在神经胶质瘤的发生、发展过程中发挥促癌作用。

关键词: 神经胶质瘤, NCAPD2, 免疫组织化学, 诊断

Abstract: Background and purpose:NCAPD2 is a protein-coding gene that plays a key role in cell proliferation, such as mitosis process. This study aimed to investigate the expression level and clinical value of NCAPD2 in glioma. Methods: The expression of NCAPD2 mRNA in various malignant tumor tissues was analyzed by GEPIA database. The expression level of NCAPD2 mRNA in glioma was analyzed by Ualcan, UCSC Xena and TIMER2.0 database. Immunohistochemical S-P method was used to detect and analyze the expression of NCAPD2 protein in normal brain tissue and glioma tissue, as well as the relationship between the overexpression of NCAPD2 protein and the clinicopathological features of glioma. The expression level of NCAPD2 in glioma cells was verified by Western blot. LinkedOmics database was used to explore genes co-expressed with NCAPD2. Metascape database and GoPlot database were used for enrichment analysis. Results: Database analysis showed that the expression of NCAPD2 was higher in various malignant tissues than in normal tissues (P < 0.05), and the expression level of NCAPD2 was higher in isocitrate dehydrogenase 1 (IDH1) mutant-type glioma than in IDH1 wild-type glioma (P < 0.05). Immunohistochemical results showed that NCAPD2 protein was mainly expressed in the nucleus and cytoplasm, and the positive expression rate and strong positive expression rate of NCAPD2 protein in glioma tissues were significantly higher than those in normal brain tissues (P < 0.01). However, NCAPD2 protein was positively correlated with clinical classification of glioma patients (P < 0.05). Western blot assay showed that the expression of NCAPD2 protein in glioma cells was significantly higher than in glial cells (P < 0.05). GO enrichment analysis showed that NCAPD2 gene was mainly related to cell cycle progression (P < 0.01). Conclusion: The overexpression of NCAPD2 in glioma is closely related to clinical grade and cell cycle progression, which indicates that NCAPD2 plays an important role in the occurrence and development of glioma.

Key words: Glioma, NCAPD2, Immunohistochemistry, Diagnosis